ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO937

Soluble Urokinase Receptor Level as Biomarker in Biopsy-Confirmed Diabetic Nephropathy

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Lupusoru, Gabriela, Fundeni Clinical Institute, Bucharest, Romania
  • Andronesi, Andreea Gabriella, Fundeni Clinical Institute, Bucharest, Romania
  • Ailincai, Ioana, Fundeni Clinical Institute, Bucharest, Romania
  • Micu, Georgia, Fundeni Clinical Institute, Bucharest, Romania
  • Sorohan, Bogdan Marian, Fundeni Clinical Institute, Bucharest, Romania
  • Obrisca, Bogdan, Fundeni Clinical Institute, Bucharest, Romania
  • Lupusoru, Mircea, UMF Carol Davila Bucharest, Bucharest, Romania
  • Fratila, Georgiana, Fundeni Clinical Institute, Bucharest, Romania
  • Ion, Oana, Fundeni Clinical Institute, Bucharest, Romania
  • Andronesi, Danut, Fundeni Clinical Institute, Bucharest, Romania
  • Ismail, Gener, Fundeni Clinical Institute, Bucharest, Romania
Background

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide associated with significant cardiovascular morbidity and mortality. The serum levels of soluble form of podocyte membrane urokinase activator receptor (suPAR) were found to be significantly elevated in patients with DN, making it a potential biomarker for assessing the severity of disease in these patients. The aim of this study was to explore the association between suPAR levels and renal pathological findings in patients with biopsy-confirmed DN.

Methods

We performed a cross-sectional study on 33 patients with biopsy-confirmed DN admitted in our department. The following clinical variables and laboratory parameters were assessed at the time of kidney biopsy: age, gender, time since DM diagnosis, BMI, arterial blood pressure (BP) values, treatment, serum creatinine, estimated glomerular filtration rate (eGFR, calculated by CKD-EPI equation), 24-hour proteinuria and suPAR levels. Histological scoring was made according to that of Tervaert et al (JASN, 2010, 21 (4) 556).

Results

33 patients were included (8 F, 25 M), with mean age 56.6±11.5 y, BMI 28,1±4,3 kg/m2, DM1 (n=4) and DM2 (n=29), months since DM diagnosis (140.7±87.9 mo), hypertensive (n=30), SBP(151.5±24.3mmHg), DBP (83.7±11,1 mmHg), eGFR (34.4± 24.8 ml/min ), serum creatinine (2.74± 1.78mg/dl), 24-hour proteinuria (2.64±2.9g/l), ACEI or ARB use (20/33). Serum suPAR levels were 7.41±3ng/ml. SuPAR levels were positively correlated with age of diabetes (r=0.363, p=0.038), serum creatinine (r=0.493, p=0.004), degree of glomerulosclerosis (r=0.405, p=0.024), degree of tubular atrophy/interstitial fibrosis (r=0.740, p<0.001), degree of arteriosclerosis (r =0.694, p<0.001), and negatively correlated with eGFR (r = -0.675, p<0.001).

Conclusion

Our study confirmed the presence of high serum levels of suPAR in patients with DN and we suggested that these are associated with age of DM, renal function, degree of glomerulosclerosis, tubular atrophy/interstitial fibrosis and arteriosclerosis. Serum suPAR might be a useful biomarker for assessing severity of renal impairment in DN, but requires future validation on larger series of patients